TIDMNCYT

RNS Number : 9597X

Novacyt S.A.

03 May 2019

Novacyt S.A.

("Novacyt" or the "Company")

Change of Adviser and Update on Directors' Disclosures

Paris, France and Camberley, UK - 3 May 2019 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, is pleased to announce the appointment of SP Angel Corporate Finance LLP as its Nominated Adviser and joint broker with immediate effect.

AIM Rule 17 disclosure

In accordance with AIM Rule 17 and Schedule Two (g) sub-paragraph (v) of the AIM Rules for Companies, the Company has been informed by Andrew Heath, Non-executive Director, that Integrated Healing Technologies, LLC a US company of which Dr Heath was a non-executive director filed a petition for bankruptcy on 9 July 2018 and entered into Chapter 7 liquidation bankruptcy on 21 February 2019.

Update to disclosures required by Schedule 2(g) of the AIM Rules for Companies

In addition to the directorships disclosed in the Company's admission document dated 18 October 2017, directors of the Company were, or had been in the past five years, at that time, directors of the following companies:

 
 Director          Additional Directorships at            Additional Directorships 
                    Admission to AIM                       held within the 5 years 
                                                           prior to Admission to 
                                                           AIM 
 James Wakefield   N/A                                    Lab 21 Limited 
 
 Graham Mullis     Lab 21 Limited, Lab 21 Healthcare      Lab 21 Diagnostics Services 
                    Limited, Primer Design Limited,        Limited, NP Tech Services 
                    Microgen Bioproducts Limited,          Limited, Myconostica 
                    Biotec Laboratories Limited,           Trustee Company Limited 
                    Selah Technologies Limited, 
                    Mercia Diagnostics Limited 
                    (subsequently dissolved), 
                    Lab21 Inc., Novacyt Asia Limited, 
                    Novacyt China Limited, Myconostica 
                    Limited 
 
 Anthony Dyer      Primer Design Limited, Selah           N/A 
                    Technologies Limited (subsequently 
                    dissolved), Microgen Bioproducts 
                    Limited, Mercia Diagnostics 
                    Limited, Biotec Laboratories 
                    Limited, Lab 21 Limited, Lab 
                    21 Healthcare limited, Lab21 
                    Inc., Novacyt Asia Limited 
 
 Edwin Snape       Sultan Scientific Limited              Lab 21 Limited 
 Jean-Pierre       SCI Crinelli-Plougrescant,             N/A 
  Crinelli          SCI Crinelli Fonciere, Alain 
                    Fresard Technologies-Micromecanique 
                    SAS

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

For further information, please refer to www.novacyt.com or contact:

- End -

Contacts

Novacyt SA

Graham Mullis, Chief Executive Officer

Anthony Dyer, Chief Financial Officer

+44 (0)1223 395472

SP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker)

Matthew Johnson / Jamie Spotswood (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

+44 (0)20 3470 0470

WG Partners (Joint Broker)

Nigel Birks / Chris Lee / Claes Spång

+44 (0) 203 705 9330

FTI Consulting (International)

Brett Pollard / Victoria Foster Mitchell/ Mary Whittow

+44 (0)20 3727 1000

brett.pollard@fticonsulting.com/victoria.fostermitchell@fticonsulting.com/ Mary.whittow@fticonsulting.com

FTI Consulting (France)

Arnaud de Cheffontaines / Astrid Villette

+33 (0)147 03 69 47 / +33 (0)147 03 69 51

arnaud.decheffontaines@fticonsulting.com / astrid.villette@fticonsulting.com

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high quality assays and reagents worldwide. The Group directly serves oncology, microbiology, haematology and serology markets as do its global partners, which include major corporates.

For more information please refer to the website: www.novacyt.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCEANSAEFKNEFF

(END) Dow Jones Newswires

May 03, 2019 02:00 ET (06:00 GMT)

Novacyt (LSE:NCYT)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Novacyt.
Novacyt (LSE:NCYT)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Novacyt.